Charles Schwab Investment Management Inc. Acquires 21,025 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Charles Schwab Investment Management Inc. raised its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 1.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 1,131,485 shares of the biopharmaceutical company’s stock after acquiring an additional 21,025 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Ocular Therapeutix were worth $9,663,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in OCUL. Intech Investment Management LLC bought a new stake in shares of Ocular Therapeutix during the 3rd quarter valued at $422,000. The Manufacturers Life Insurance Company increased its position in shares of Ocular Therapeutix by 11.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 130,202 shares of the biopharmaceutical company’s stock valued at $1,133,000 after buying an additional 13,238 shares in the last quarter. FMR LLC increased its position in shares of Ocular Therapeutix by 7,098.7% in the 3rd quarter. FMR LLC now owns 434,369 shares of the biopharmaceutical company’s stock valued at $3,779,000 after buying an additional 428,335 shares in the last quarter. Verition Fund Management LLC bought a new stake in shares of Ocular Therapeutix in the 3rd quarter valued at $544,000. Finally, Knoll Capital Management LLC increased its position in shares of Ocular Therapeutix by 199.6% in the 3rd quarter. Knoll Capital Management LLC now owns 600,400 shares of the biopharmaceutical company’s stock valued at $5,223,000 after buying an additional 400,000 shares in the last quarter. Institutional investors own 59.21% of the company’s stock.

Insider Transactions at Ocular Therapeutix

In other news, insider Donald Notman sold 11,119 shares of the stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $7.81, for a total transaction of $86,839.39. Following the completion of the transaction, the insider now directly owns 193,444 shares in the company, valued at $1,510,797.64. This represents a 5.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Pravin Dugel sold 21,475 shares of the stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $6.87, for a total transaction of $147,533.25. Following the transaction, the insider now owns 3,520,318 shares of the company’s stock, valued at approximately $24,184,584.66. This represents a 0.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 38,895 shares of company stock worth $283,772 in the last three months. Insiders own 3.50% of the company’s stock.

Ocular Therapeutix Price Performance

Shares of NASDAQ OCUL opened at $7.51 on Friday. The firm has a market cap of $1.19 billion, a PE ratio of -5.69 and a beta of 1.34. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. Ocular Therapeutix, Inc. has a 1-year low of $4.06 and a 1-year high of $11.78. The company has a fifty day moving average price of $7.57 and a 200 day moving average price of $8.78.

Ocular Therapeutix (NASDAQ:OCUL) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05). The company had revenue of $17.08 million during the quarter, compared to analyst estimates of $16.89 million. Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. Research analysts predict that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on OCUL shares. Needham & Company LLC started coverage on shares of Ocular Therapeutix in a research report on Tuesday, March 11th. They issued a “buy” rating and a $15.00 price objective for the company. Royal Bank of Canada started coverage on shares of Ocular Therapeutix in a research report on Tuesday, March 18th. They issued an “outperform” rating and a $17.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. Finally, JMP Securities set a $19.00 price objective on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $16.38.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.